Coherus Oncology Statistics
Total Valuation
CHRS has a market cap or net worth of $86.63 million. The enterprise value is $303.72 million.
Important Dates
The next estimated earnings date is Thursday, August 7, 2025, after market close.
| Earnings Date | Aug 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CHRS has 115.93 million shares outstanding. The number of shares has increased by 12.48% in one year.
| Current Share Class | 115.93M |
| Shares Outstanding | 115.93M |
| Shares Change (YoY) | +12.48% |
| Shares Change (QoQ) | +0.38% |
| Owned by Insiders (%) | 4.33% |
| Owned by Institutions (%) | 53.99% |
| Float | 110.89M |
Valuation Ratios
The trailing PE ratio is 1.75.
| PE Ratio | 1.75 |
| Forward PE | n/a |
| PS Ratio | 0.32 |
| Forward PS | 1.40 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 173.25 |
| P/OCF Ratio | 173.25 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.12 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 607.43 |
Financial Position
The company has a current ratio of 1.22
| Current Ratio | 1.22 |
| Quick Ratio | 0.57 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | 599.00 |
| Interest Coverage | -3.15 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -9.10% |
| Return on Invested Capital (ROIC) | -20.04% |
| Return on Capital Employed (ROCE) | -71.21% |
| Revenue Per Employee | $1.19M |
| Profits Per Employee | -$574,285 |
| Employee Count | 228 |
| Asset Turnover | 0.48 |
| Inventory Turnover | 3.63 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -53.88% in the last 52 weeks. The beta is 0.88, so CHRS's price volatility has been lower than the market average.
| Beta (5Y) | 0.88 |
| 52-Week Price Change | -53.88% |
| 50-Day Moving Average | 0.88 |
| 200-Day Moving Average | 1.07 |
| Relative Strength Index (RSI) | 40.11 |
| Average Volume (20 Days) | 1,200,012 |
Short Selling Information
The latest short interest is 32.53 million, so 28.06% of the outstanding shares have been sold short.
| Short Interest | 32.53M |
| Short Previous Month | 33.12M |
| Short % of Shares Out | 28.06% |
| Short % of Float | 29.34% |
| Short Ratio (days to cover) | 21.43 |
Income Statement
In the last 12 months, CHRS had revenue of $272.25 million and -$130.94 million in losses. Loss per share was -$1.14.
| Revenue | 272.25M |
| Gross Profit | 153.48M |
| Operating Income | -82.62M |
| Pretax Income | -29.72M |
| Net Income | -130.94M |
| EBITDA | -77.80M |
| EBIT | -82.62M |
| Loss Per Share | -$1.14 |
Full Income StatementBalance Sheet
The company has $82.41 million in cash and $299.50 million in debt, giving a net cash position of -$217.09 million or -$1.87 per share.
| Cash & Cash Equivalents | 82.41M |
| Total Debt | 299.50M |
| Net Cash | -217.09M |
| Net Cash Per Share | -$1.87 |
| Equity (Book Value) | -183.47M |
| Book Value Per Share | -1.58 |
| Working Capital | 55.13M |
Full Balance SheetCash Flow
| Operating Cash Flow | 500,000 |
| Capital Expenditures | n/a |
| Free Cash Flow | 500,000 |
| FCF Per Share | $0.00 |
Full Cash Flow StatementMargins
Gross margin is 56.38%, with operating and profit margins of -30.35% and -48.09%.
| Gross Margin | 56.38% |
| Operating Margin | -30.35% |
| Pretax Margin | 18.05% |
| Profit Margin | -48.09% |
| EBITDA Margin | -28.58% |
| EBIT Margin | -30.35% |
| FCF Margin | 0.18% |
Dividends & Yields
CHRS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -12.48% |
| Shareholder Yield | -12.48% |
| Earnings Yield | -151.15% |
| FCF Yield | 0.58% |
Analyst Forecast
The average price target for CHRS is $4.68, which is 526.34% higher than the current price. The consensus rating is "Buy".
| Price Target | $4.68 |
| Price Target Difference | 526.34% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | -2.58% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CHRS has an Altman Z-Score of -5.71 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.71 |
| Piotroski F-Score | 6 |